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CLINICAL INVESTIGATION
Dyslipoproteinemia in diabetic renal failure
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Dyslipoproteinemia in diabetic renal failure. Plasma concentrations of
lipids and apolipoproteins (Apo) were determined in 34 patients with
long-standing type I (insulin-dependent) diabetes mellitus. Twenty-four
patients had renal insufficiency (GFR 4 to 55 mI/mm) due to diabetic
nephropathy, while 10 patients had no clinical signs of nephropathy.
Results were compared with those in 42 non-diabetic patients with
comparable degree of renal insufficiency and with asymptomatic control
subjects. Diabetic patients without nephropathy had plasma lipid and
apolipoprotein concentrations similar to those of the control subjects.
Diabetic patients with renal insufficiency had a significant increase in
triglycerides (TG) and, to a lesser extent, in total cholesterol (TC). The
patients also had reduced levels of ApoA-I and ApoA-II, increased
levels of ApoC-Il and ApoC-Ill, while increases in levels of ApoB and
ApoE were statistically significant in patients with GFR < 20 mI/mm.
These lipids and apolipoprotein abnormalities were accentuated with
decreasing renal function. The reduction in the ApoA-I/ApoC-III ratio
characteristic of renal insufficiency was found in normo- and hyper-TG
diabetic patients with nephropathy; this ratio was correlated with the
GFR levels. Patients with higher HbA1C values had higher levels of
ApoC-Il and ApoC-HI. The findings in the diabetic patients corre-
sponded with those in non-diabetic patients with renal insufficiency.
However, diabetic patients had higher ApoC-Ill and ApoE levels. The
abnormalities of lipid metabolism in diabetic renal insufficiency seem to
reflect primarily metabolic impairments characteristic of renal insuffi-
ciency, but may be further accentuated by the diabetic state and the
metabolic control.
Patients with diabetic nephropathy and renal failure consti-
tute one of the largest diagnostic groups of patients treated for
end-stage renal failure with dialysis and transplantation [1]. The
clinical course of these patients is characterized by a high
incidence of atherosclerotic complications such as cardiovas-
cular and peripheral vascular disease [1—4]. Disturbances of
lipid metabolism are an inherent feature of renal insufficiency
[5—8] and these abnormalities also affect the diabetic patients.
On the other hand, the diabetic state without renal disease is
also characterized by alterations of lipid metabolism [9, 101.
These two metabolic factors may synergistically contribute to
the complex pathogenesis of the dyslipoproteinemia in these
patients, with the development of atherosclerosis as the possi-
ble consequence.
Determination of the protein moieties of the lipoproteins, the
Received for publication June 5, 1991
and in revised form June 3, 1992
Accepted for publication July 2, 1992
© 1992 by the International Society of Nephrology
apolipoproteins, provides important means for identifying and
classifying dyslipoproteinemias and very useful clues about the
chemical nature of the corresponding lipoprotein particles de-
fined by their apolipoprotein composition [11]. To evaluate the
effect of renal failure and diabetes, we have determined the lipid
and apolipoprotein profiles in plasma of patients with long-
standing insulin-dependent diabetes mellitus and renal insuffi-
ciency in the predialytic stage, and compared these findings
with those in non-diabetic patients with a similar degree of renal
insufficiency on one hand and diabetic patients without renal
disease on the other.
Methods
Diabetic patients
Thirty-four patients (22 men and 12 women) with insulin-
dependent diabetes mellitus (type I) were studied. The clinical
characteristics of patients are shown in Table 1.
Ten patients (8 men, 2 women) had no clinical signs of
nephropathy: they had no albuminuria as measured by repeated
dip-sticks and normal serum creatinine levels. Urinary albumin
concentrations were determined in all patients within a year
from the study and did not exceed 6 mg/liter in any patient.
Their mean age was 45.2 14.8 years (range 28 to 65) and they
had a mean duration of diabetes of 25.0 10.7 years. The
patients were in good physical condition without signs of major
vascular complications. They were treated with combinations
of long and short-acting insulin regimens or in two cases with
insulin pumps. Two patients were treated for hypertension with
cardioselective beta-blocking antihypertensive drugs. The pa-
tients had no concomitant disease considered to significantly
influence nutrition or lipid metabolism. They were selected to
represent patients characterized by a similar duration of disease
as the patients with renal disease and by an adequate metabolic
control and treated at the same hospital.
Twenty-four patients had renal insufficiency judged to be
caused by diabetic nephropathy. There were 14 men and 10
women with a mean age of 42.9 8.9 years. The mean duration
of diabetes was 27.3 6.3 years. Neither age nor diabetes
duration differed significantly from diabetic controls without
nephropathy. All patients had reduced renal function measured
as the glomes-ular filtration rate (GFR) [12] with a mean value of
21.5 13.8 mllmin/l.73 m2 body surface area. The mean
concentration of glycated hemoglobin (HbA1 ) was 9.3 1.3%,
which was not significantly different from that in the diabetic
controls without nephropathy (P = 0.053). Twenty-two patients
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Table 1. Clinical characteristics of patients with diabetes mellitus with and without nephropathy and of non-diabetic patients with renal
insufficiency
Diabetic patients
ic patients
No nephropathy
Nephropathy Nondiabet
GFR > 20 mI/mm GFR  20 ml/min GFR> 20 mI/mm GFR 20 mllmin
N 10 10 14 15 27
M/F 8/2 5/5 9/5 9/6 12/15
Age, years 45.2 14.6 41.2 5.5 43.9 10.8 45.7 12.7 47.2 13.1
BMI, kg/rn2 22.7 3.0 24.8 4.2 22.5 3.8 23.6 2.4 25.4 5.7
HbAIC, % 8.4 1.3 9.3 1.0 9.4 1.5 — —
Serum creatinine, srnol/liter 90.4 11.9 172.1 42.9 378.9 164.9 161.3 24.5 572.9 186.5
GFR, ml/rnin 35.0 10.7 11.7 5.0 41.7 12.0 9.3 4.0
Serum protein, glliter 64.2 13.1 69.0 7.0
N=13
65.1 5.1 65.9 6.1
N=26
24 hr urinary protein excretion, g 1.5 1.4 3.0 1.8N=12
1.2 0.9 1.8 1.0
N=17
Hypertension 2 10 12 11 26
Treatment with 13-blockers 2 8 11 9 24
were treated for hypertension mostly with cardioselective beta
blockers (19 patients) and furosemide. Macrovascular compli-
cations in coronary, cerebral or major peripheral vessels were
present or developed within a few years after the study in 15
patients. The patients had increased 24-hour urinary protein
excretion, ranging from 0.3 to 7.0 g (mean 2.3 1.8) at the time
of study in 22 patients. However, none of the patients was
severely nephrotic, and the lowest recorded serum albumin
concentration was 26 gfliter with a mean value of 40.5 8.7
glliter. There was no evidence of other primary renal disease.
Renal biopsy was performed for reasons not related to the
present study in 15 patients and only revealed changes compat-
ible with diabetic nephropathy. The remaining nine patients had
a duration of diabetes until manifest proteinuria of nine to 19
years and they all had diabetic retinopathy.
The patients with nephropathy were further separated ac-
cording to their renal function in order to evaluate its influence
on lipoprotein metabolism. Ten patients had a less advanced
renal insufficiency with GFR values > 20 mi/mm, mean 35.0
10.7 (range 22 to 55). Fourteen patients had advanced renal
failure with GFR  20 ml/min, mean 11.7 5.1 (range 5 to 20).
The clinical characteristics of these two patient groups are
shown in Table 1. Patients with nephropathy were treated with
insulin regimens of repeated doses of short-acting insulin com-
bined with medium or long-acting insulin, and most patients
monitored their blood glucose homeostasis by self-control. In
addition to the antihypertensive and diuretic drugs, treatment
with phosphate binders, sodium bicarbonate, and vitamins was
used as appropriate. All diabetic patients received dietary
counseling for their diabetes but no specific counseling on lipid
lowering diets. A limited number of patients with severely
restricted renal function and impending uremia were proscribed
a moderate dietary protein restriction. None of the patients was
treated with steroids or immunosuppressive agents or drugs
known to influence lipid metabolism. All patients were treated
at the Departments of Nephrology and Medicine, University of
Goteborg.
Non-diabetic patients with renal insufficiency
Forty-two patients with renal insufficiency from primary
renal diseases other than diabetes mellitus but with similar
range of age and GFR as the diabetic patients were studied as a
non-diabetic reference patient population. These patients have
been described previously [13]. The clinical characteristics are
summarized in Table 1. There were 21 men and 21 women with
a mean age of 45.2 12.6 years and 48.4 13.2 years,
respectively. Their mean GFR was 20.9 17.5 mi/min/! .73 m2
BSA. The renal diagnosis was chronic glomerulonephritis in 17,
chronic interstitial nephritis in 14, polycystic kidney disease in
six, and other or undetermined diagnosis in five patients.
Thirty-seven patients were treated for hypertension mostly with
cardioselective beta blockers (33 patients) and diuretics. Fifteen
patients had GFR> 20 mllmin, mean 39.5 11.3 (range 21 to
62). Twenty-seven patients had GFR 20 mi/mm, mean 9.1
4.0 (range 5 to 19). The 24-hour urinary protein excretion
ranged from 0.1 to 2.6 g in patients with GFR> 20 mi/mm, and
from 0.6 to 4.1 g in patients with GFR  20 ml/min. Data on
24-hour protein excretion at time of study were not available in
10 patients with GFR  20 mllmin. All but one of these patients
had positive qualitative test for albuminuria and serum protein
concentrations ranging from 62 to 72 g!liter. None of the 42
patients had clinical evidence of nephrotic syndrome at the time
of study, or other conditions or treatment that would affect lipid
metabolism as previously described [131.
Control subjects
Control subjects were recruited from among apparently
healthy asymptomatic Swedish and American subjects, em-
ployees of the Department of Nephrology, University of GOte-
borg, Sweden, and the Oklahoma Medical Research Founda-
tion, Oklahoma, USA, as previously described [13], There were
48 men and 58 women with a mean age of 49.5 12.9 years and
46.9 13.8 years, respectively.
Lipid and apolipoprotein analyses
Blood samples were drawn after an overnight fast by antecu-
bital venipuncture. Plasma samples contained EDTA (1 mg/ml)
and €-aminocaproic acid (1.3 mglml) as preservatives. The
refrigerated samples were shipped by air freight to Oklahoma
City and analyses were performed three to four days after blood
collection. Serum creatinine, plasma and urine protein concen-
trations and giycated hemoglobin (HbA1) were determined at
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Table 2. Plasma lipid and lipoprotein cholesterol concentrations in patients with diabetes mellitus with and without nephropathy and in non-
diabetic patients with renal insufficiency
Subjects Triglycerides
Cholesterol, mmol/liter
Total VLDL LDL HDL
Normal subjects X
(SD)
N
1.00
(0.38)
105
5.28 0.36
(0.80) (0.19)
105 76
3.45
(0.78)
83
1.49
(0.40)
93
Diabetic patients
Patients without nephropathy X
(SD)
N
0.74
(0.19)
10
5.06 0.34
(1.04) (0.08)
10 10
3.16
(0.92)
10
1.56
(0.32)
10
Patients with nephropathy
GFR> 20 mllmin X
(SD)
N
l.65'
(1.14)
10
5.52 0.6O0,
(1.05) (0.11)
10 9
3.16
(1.13)
9
l.65a
(0.22)
9
GFR 20 mI/mm X
(SD)
N
3.28
(1.34)
14
700c.d 136c,fg
(1.92) (0.54)
14 13
4.11
(1.45)
13
116h
(0.41)
14
Non-diabetic patients with renal
insufficiency
GFR> 20 mI/mm X
(SD)N
l.26a
(0.49)
15
5.50 0.58c
(1.10) (0.22)
15 15
3.64
(1.01)
15
j,28h
(0.35)
15
GFR s 20 mI/mm X
(SD)
N
2.42
(1.60)
27
6.43c 0.91m
(1.77) (0.47)
27 18
3.92
(1.44)
16
114b
(0.41)
16
Significance of difference between means
P: <0.05 <0.01 <0.001 P: <0.05 <0.01 <0.001
vs. normal subjects a b c vs. diabetic patients without nephropathy d e f
vs. diabetic patients with nephropathy, g h i vs. diabetic patients with nephropathy j k IGFR >20 ml/min GFR  20 mI/mm
vs. non-diabetic patients with renal m n o
insufficiency,
GFR> 20 mI/mm
Significance of difference between diabetic patients without nephropathy and non-diabetic patients with renal insufficiency and between diabetic
and non-diabetic patients in non-identical GFR groups is not shown.
the time of sampling for lipid and apolipoprotein measurements
by the Department of Clinical Chemistry, University of GOte-
borg, at this hospital.
Total cholesterol (TC), triglyceride (TO) and lipoprotein
cholesterol concentrations were determined as previously de-
scribed [14]. Apolipoprotein analyses were carried out by
electro-immunoassays according to previously described pro-
cedures for ApoA-I and ApoA-II [l5}, ApoB [16], ApoC-Il [17],
ApoC-Ill [181 and ApoE [19].
GFR was determined as the 51Cr EDTA clearance by the
Departments of Clinical Chemistry and Clinical Physiology,
University of Goteborg [12]. Glycated hemoglobin was deter-
mined by an HPLC-method using ion exchange chromatogra-
phy on Mono STM from Pharmacia Fine Chemicals AB, Swe-
den. The reference interval in young adults is 3.7 to 5.1%.
Statistical methods
Means, SD and SEM were calculated by conventional meth-
ods. Wilcoxon's two sample tests were used for testing the
significance of differences between means, and the correlational
coefficients were calculated by Pearson's correlation method.
Multiple linear regression was calculated using the SAS® Gen-
eral Linear Models procedure.
Results
Lipids and apolipoproteins
There were no differences in the concentrations of plasma
TG, TC or lipoprotein cholesterol between diabetic patients
without nephropathy and control subjects (Table 2). However,
diabetic patients with nephropathy had significantly increased
concentrations of TG and very low density lipoprotein (VLDL)-
cholesterol (P < 0.001) and, to a lesser degree, of TC (P < 0.05)
in comparison with normal controls or diabetics without renal
insufficiency.
The patient population with GFR 20 mllmin differed from
normal controls by significantly higher concentrations of TG,
TC and VLDL-cholesterol and lower concentrations of high
density lipoprotein (HDL)-cholesterol. The patient subpopula-
tion with GFR > 20 mI/mm also differed significantly from
normal controls by higher levels of TG and VLDL-cholesterol;
however, the levels of HDL-cholesterol were significantly
higher than in normal controls. Neither of these two subpopu-
lations differed from controls in the levels of low density
lipoprotein (LDL)-cholesterol. A comparison between the two
subpopulations of diabetic patients with nephropathy revealed
that patients with GFR  20 mllmin had significantly higher
________________________________________________________________________
Fig. 1. Relationship between glomerular
filtration rate (GFR) and plasma triglyceride
0 10 20 30 40 50 60 70 concentrations in patients with diabetic
nephropa thy (solid circles) and patients with
GFR, mi/mm non-diabetic renal insufficiency (open circles).
concentrations of TG and VLDL-cholesterol and significantly
lower levels of HDL-cholesterol that patients with GFR > 20
mi/mm. Elevated triglycerides were encountered more fre-
quently in patients with GFR  20 mllmin than in patients with
GFR> 20 mlImin; in the former group 12/14 patients (86%) had
TG values above 1 SD of controls (1.38 mmol/liter) in compar-
ison with 4/10 (40%) patients in the latter group (Fig. 1).
Lipid concentrations in plasma of diabetic patients with
nephropathy were compared with those of non-diabetic patients
with similar degree of renal insufficiency from the same hospi-
tal. As shown in Table 2, diabetic patients with moderate renal
insufficiency (GFR> 20 mllmin) had significantly higher HDL
cholesterol, but no difference was found in total cholesterol or
TG levels. In advanced renal failure (GFR  20 ml/min) diabetic
patients had a further significant increase in the concentrations
of TG and VLDL-cholesterol (Fig. 1).
There was no significant difference in the plasma apolipopro-
tein concentrations between diabetic patients without nephrop-
athy and controls except for a slightly lower concentration of
ApoB in diabetics (Table 3). In contrast, diabetic patients with
renal insufficiency had significantly lower plasma concentra-
tions of ApoA-I and ApoA-II (P < 0.001) than normal controls.
Fourteen out of 24 patients (58%) had ApoA-I levels below 1 SD
of the control population (115.4 mg/dl). Most patients with
reduced ApoA-I were found among those with GFR  20
ml/min (11 of 14 or 79% of patients). In addition, 15 out of 17
patients (88%) had ApoA-II levels below I SD of the control
population (51.2 mg/dl). A slightly increased concentration of
ApoB (P = 0.058) in diabetic patients was mainly due to higher
levels of ApoB among patients with GFR 20 mI/mm than
patients with GFR> 20 ml/min. In the former group 9/14 (64%)
patients had ApoB concentrations above 1 SD of the control
population (128.6 mgldl) in contrast to only 2/10 patients in the
latter group. The concentrations of apolipoproteins C-Il (P <
0.01) and C-Ill (P < 0.001) were significantly higher in diabetic
patients with renal insufficiency than in normal controls. In fact,
increased levels of ApoC-Ill were the most characteristic
feature of apolipoprotein profile in this patient population with
21 of 23 (91%) patients having ApoC-Ill values higher than 1 SD
of normal controls (11.6 mg/dl, Fig. 2). Whereas ApoC-Ill
levels were significantly higher in both diabetic subpopulations
than in controls, the levels of ApoC-Il were significantly higher
only in patients with GFR 20 mI/mm. The whole group of
diabetic patients with nephropathy had slightly but not signifi-
cantly higher (P = 0.054) levels of ApoE than controls. Again,
this difference was mainly due to the subpopulation of patients
with GFR 20 ml/min in whom 9 of 14 (64%) patients had
ApoE levels above 1 SD of control subjects (16.2 mgldl); the
ApoE levels of patient subpopulations with GFR > 20 ml/min
were within the normal range. A comparison between the two
diabetic subpopulations with renal insufficiency only showed
significant differences (P < 0.05) in the levels of ApoC-Ill and
ApoE both being higher in patients with GFR  20 mllmin than
in patients with GFR> 20 mllmin.
When compared with the non-diabetic patients with compa-
rable degree of renal insufficiency, the diabetic patients with
GFR 20 ml/min had slightly lower levels of ApoA-II and
significantly higher levels of ApoC-Ill and ApoE (Table 3, Fig.
2). There were no significant differences in apolipoprotein
concentrations between diabetic and non-diabetic patients with
GFR> 20 mllmin.
The impairments in lipoprotein metabolism are also reflected
in various concentration ratios of apolipoproteins. The charac-
teristic apolipoprotein ratios in diabetic patients without ne-
phropathy were very similar to those of normal control sub-
jects. In contrast, diabetics with renal insufficiency had
significantly higher (P < 0.001) values of ApoA-I/ApoA-II (3.11
vs. 2.21) and ApoC-III/ApoE (1.56 vs. 0.84) and significantly
lower (P < 0.001) values of ApoA-I/ApoB (1.02 vs. 1.43) and
ApoA-I/ApoC-III (6.30 vs. 16.53) than controls. The signifi-
cantly reduced ApoA-I/ApoC-III ratio is considered as the
hallmark of renal dyslipoproteinemia [5, 13]. Among diabetics
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Table 3. Plasma apolipoprotein concentrations in patients with diabetes mellitus with and without nephropathy and in non-diabetic patients
with renal insufficiency
Subjects
Apolipoproteins, mg/dl
A-I A-Il B C-Il C-Ill E
Normal subjects X
(SD)
N
144.1
(28.7)
101
66.6 105.0 3.3
(15.4) (23.6) (1.0)
94 103 32
9.1
(2.5)
101
12.0
(4.2)
97
Diabetic patients
Patients without nephropathy X
(SD)
N
137.1
(44.0)
10
62.1 86.0 3.4
(16.7) (21.9) (0.6)
10 10 10
9.2
(2.9)
10
12.3
(3.0)
10
Patients with nephropathy
GFR > 20 mI/mm X
(SD)
N
l21.l
(25.0)
10
368c,d 106.3 3.8
(10.7) (32.0) (1.4)
6 10 8
17.l
(6.8)
10
12.2
(7.3)
10
GFR 20 mi/mm X
(SD)
N
101.1"'
(23.5)
14
388c,d 1442a,d 5.6"'
(14.8) (60.3) (2.0)
11 14 12
268.g
(9.6)
13
207,g
(11.3)
14
Non-diabetic patients with renal
insufficiency
GFR>20m1/min X
(SD)
N
ll4.5
(21.8)
15
49.0" 110.3 2.9
(14.6) (40.1) (0.7)
9 15 10
13.8c
(3.2)
15
13.0
(3.4)
15
GFR  20 mI/mm X
(SD)
N
98.1c
(25.1)
27
454C 134.0c
(9.7) (46.3) (1.8)
18 27 15
17.8'
(7.3)
27
l0,6cm
(4.4)
24
P: <0.05 <0.01 <0.001
Significance of difference between means
P: <0.05 <0.01 <0.001
vs. normal subjects a b c vs. diabetic patients without nephropathy d e f
vs. diabetic patients with nephropathy, g h i vs. diabetic patients with nephropathy j k 1
GFR> 20 mI/mm GFR  20 mi/mm
vs. non-diabetic patients with renal m n o
insufficiency,
GFR> 20 mllmin
Significance of difference between diabetic patients without nephropathy and non-diabetic patients with renal insufficiency and between diabetic
and non-diabetic patients in non-identical GFR groups is not shown.
with nephropathy 20 of 23 (87%) patients had ApoA-I/ApoC-III
below 1 SD of the control subjects (11.9). The ApoA-I/ApoC-III
ratio decreased with decreasing GFR values. The decrease in
this apolipoprotein ratio resulted primarily from increased
levels of ApoC-Ill in nearly all patients and from reduced levels
of ApoA-I mainly in patients with GFR 20 mI/mm. The
ApoA-I/ApoB ratio, considered one of the useful predictors of
coronary artery disease [20], decreased with decreasing GFR
values. Diabetic patients with nephropathy only differed from
non-diabetic patients with renal insufficiency with respect to a
higher ApoA-I/ApoA-II ratio.
Relationships of lipid and apolipoproteins with renal function
and metabolic control
The influence of renal function on the development of lipid
and apolipoprotein abnormalities in diabetic patients was eval-
uated from their correlations with the GFR (Table 4). Thus,
there was a significant inverse correlation between the GFR
values and concentrations of TG and ApoC-Ill (Figs. 1 and 2),
and an equally significant but positive correlation between the
GFR values and HDL-cholesterol levels and the ApoA-I/ApoC-
III ratio.
A decrease in GFR values was also accompanied by in-
creased urinary protein excretion (Table 4). The 24-hour uri-
nary protein excretion was significantly correlated with the
levels of TG and negatively correlated with HDL-cholesterol
and ApoA-I/ApoC-III ratio. Serum albumin levels were signif-
icantly correlated only with the TO levels (r = —0.57, P < 0.05,
N = 17). However, the magnitude of 24 hour protein excretion
(lower and higher than 3.5 g) had no effect on lipid and
apolipoprotein levels in diabetic patients (Table 5).
To evaluate the effect of metabolic control in diabetic patients
with renal insufficiency, patients with nephropathy were sepa-
rated into two groups according to HbAIC values above (N =
11) or below (N = 13) the mean value (9.5%) of 23 patients.
Patients with higher HbAIC values had slightly but not signifi-
cantly higher TO values (3.04 vs. 2.21 mmollliter, P = 0.15).
They had, however, significantly increased levels of ApoC-Il
(6.4 vs. 3.7 mgldl, P = 0.01) and ApoC-Ill (28.0 vs. 17.5 mg!dl,
P = 0.03) and a higher concentration of ApoB (144.2 vs. 112.9
mgldl, P = 0.16) and ApoE (19.1 vs. 15.7 mg!dl, P = 0.45). The
HbAIC values of the whole diabetic population were signifi-
cantly correlated with the levels of VLDL-cholesterol, ApoC-
II, and ApoC-Ill (Table 4).
Evaluation of the relative contribution of renal function
(GFR) and metabolic control (HbA,) to selected lipid and
o 0 • .
Table 4. Pearson correlation coefficients (r values) between renal
function (GFR) proteinuria and metabolic control (HbA1 values) and
lipid, lipoprotein and apolipoprotein concentrations in diabetic
patients with nephropathy
GFR
24-hr urinary
protein excretion HbA1C
Triglycerides 0.45a 0.28
Cholesterol —0.25 0.21 0.06
VLDL-cholesterol 0.45a O.44a
LDL-cholesterol —0.25 0.23 —0.08
HDL-cholesterol 0,52b —0.18
ApoA-I 0.29 —0.36 —0.09
ApoA-II 0.05 —0.24 —0.10
ApoB —0.30 0.03 0.24
ApoC-Il —0.41 0.42 0,60b
ApoC-Ill 0.42 0,56b
ApoE —0.38 0.39 0.08
ApoA-I/ApoB 0.39 —0.32 —0.22
ApoA-I/ApoC-III 0.41a 0.48a —0.21
GFR — O.45a —0.23
a p 0.05; b p < 0.01
apolipoprotein variables were performed with multiple regres-
sion analysis using GFR and HbAIC as independent variables.
With TG as the dependent variable only GFR, but not HbA1C,
was shown to contribute. On the other hand, for ApoC-Il and
ApoC-Ill, the regression coefficients were 0.85 (F = 7.54, P =
0.014) and 3.77 (F = 6.57, P = 0.019) for HbAIC and —0.06 (F
= 3.93, P = 0.065) and —0.28 (F = 4.83, P = 0.041) for GFR,
respectively. Thus, both the degree of metabolic control and
renal function contributed to the ApoC-Il and ApoC-Ill levels.
Discussion
This study was designed to determine the abnormal lipid and
apolipoprotein profiles in plasma of insulin-dependent diabetic
patients with nephropathy and renal insufficiency. Whereas the
adequately controlled insulin-dependent diabetic patients with-
out nephropathy, but equally long duration of diabetes, had
Table 5. Plasma lipid and apolipoprotein concentrations in diabetic
patients in relation to 24 hour urinary protein excretion
24 hr urmary protein excretion
Significance
3.5 g >3.5 g of(N = 17) (N = 5) difference
GFR, mI/mm 24.8 14.8 14.2 8.4 NS
Triglycerides, 2.53 1.63 3.05 0.99 NS
mmol/liter
Cholesterol, 6.61 2.0 5.98 1.30 NS
mmol/liter
VLDL-cholesterol, 0.99 0.58 1.28 0.54 NS
mmollliter
LDL-cholesterol, 3.46 1.16 4.62 1.92 NS
mmol/liter
HDL-cholesterol, 1.43 0.40 1.25 0.50 NS
mmol/Iiter
ApoA-I, mg/dl 111.0 24.1 109.1 36,9 NS
ApoA-II, mg/dl 39.3 11.8 35.5 20.8 NS
ApoB, mg/dl 124.1 52.2 139.2 61.7 NS
ApoC-Ill, ing/di 20.4 9.1 28.0 6.2 NS
ApoE, mg/dl 15.6 10.8 18.1 5.9 NS
normal concentrations of plasma lipids and apolipoproteins [9],
the altered lipid and apolipoprotein profiles of diabetic patients
with nephropathy resembled those of non-diabetic patients with
comparable degree of renal insufficiency [13, 14]. These abnor-
malities mainly stemmed from and reflected changes in the
composition and concentration of TG-rich ApoB-containing
lipoproteins in VLDL and LDL on one hand, and ApoA-
containing high density lipoproteins on the other. In addition to
a moderate elevation of TG and VLDL-cholesterol levels, both
diabetics and non-diabetics with renal insufficiency had signif-
icantly increased concentrations of ApoC-peptides. Both
groups of renal patients had reduced levels of apolipoproteins
A-I and A-Il, and patients with GFR  20 ml also had reduced
levels of HDL-cholesterol. There was no significant increase in
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Fig. 2. Relationship between glomerular
0 __________________________________________________________________ filtration rate (GFR) and plasma
apolipoprotein C-Ill (ApoC-Ill)
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the levels of LDL-cholesterol, and ApoB levels were only
increased in patients with GFR 20 mllmin. In fact, all
characteristic lipid and apolipoprotein abnormalities were
found to be exacerbated with the progression of renal disease in
both diabetic and non-diabetic patients. We have reported
previously that, as a consequence of altered apolipoprotein
profile, the reduced ratio of ApoA-I/ApoC-III is considered as
the hallmark of dyslipoproteinemia characteristic of non-dia-
betic renal insufficiency [13, 141. This study has shown that the
reduced ApoA-I/ApoC-III ratio is also one of the most charac-
teristic features of apolipoprotein profile in diabetic patients
with renal insufficiency, including those with normal levels of
TG. In diabetics with GFR 20 ml/min the mean value of
ApoA-I/ApoC-III ratio was as low as 25% of that characterizing
normal controls. Based on apolipoprotein profiles as useful
clues, the dyslipoproteinemia of diabetic and non-diabetic pa-
tients with renal insufficiency seems to be characterized by the
accumulation of TG-rich ApoB-containing lipoprotein particles
with ApoC and ApoE as minor apolipoprotein constituents. The
other lipoprotein particle abnormality shared by both patient
groups is the reduced concentration of ApoA-containing li-
poprotein particles.
The separation of diabetic and non-diabetic patients accord-
ing to their residual GFR is arbitrary, and is based on the
clinical observations that, at a GFR value around 20 mi/mm, the
metabolic consequences of renal failure begin to appear such as
calcium and phosphate imbalance, significant retention of ni-
trogenous compounds including urea, metabolic acidosis and
renal anemia. Patients with GFR values higher than 20 mI/mm
are generally asymptomatic with respect to their renal insuffi-
ciency; however, the results of this and our previous studies
[13] and those of others [21] indicate that significant alterations
of lipoprotein metabolism are present but without overt hyper-
lipidemia. As shown in Figure 1, there seems to be at this GFR
level a dividing point below which TG levels are increased in
the diabetic patients.
Although it appears that most of the lipoprotein abnormalities
in diabetic patients with nephropathy are closely related to their
renal disease, there are some differences in the lipid and
apolipoprotein profiles between diabetic and non-diabetic renal
patients that most probably depend on and result from diabetes
and the efficacy of its metabolic control. As a group, diabetic
patients had significantly higher levels of ApoC-Ill and ApoE (P
<0.02) than non-diabetic patients. These differences appear to
be accentuated with reduction in renal function as shown by the
significantly increased levels of TG, ApoC-Ill and ApoE in
diabetic patients with GFR 20 mI/mm; these differences were
less marked in patients with GFR > 20 mi/mm (Figs. 1 and 2).
When evaluated in terms of their metabolic controls (glycated
hemoglobin levels), diabetic patients with poorer control had
higher levels of plasma TG, VLDL-cholesterol, ApoC-Il,
ApoC-Ill and ApoE than patients whose primary disease was
better controlled. This suggests that, also in renal failure, a
suboptimal metabolic control may accentuate lipoprotein ab-
normalities qualitatively resembling those of ketoacidosis, that
is, high levels of ApoC- and ApoE-containing TG-rich lipopro-
teins [9, 22].
Marked proteinuria with the clinical manifestations of ne-
phrotic syndrome has often been regarded as an integral feature
of diabetic nephropathy and could contribute significantly to the
lipoprotein abnormalities in these patients. However, adequate
control of hypertension with conventional antihypertensive
therapy or even more efficiently with angiotensin-converting
enzyme inhibitors may considerably reduce the proteinuria, and
nephrotic syndrome is no longer a regular finding in diabetic
patients with nephropathy [23, 24]. In this study only five
diabetic patients had a 24 hour protein excretion of more than
3.5 g and the lowest serum albumin level was 26 g/liter.
Although there was a correlation between the 24 hour urinary
protein excretion and triglyceride and ApoC-Il and ApoC-Ill
levels, the contributory influence of proteinuria in some pa-
tients cannot be separated from the effect of reduced GFR
values. As shown in Table 5, there were no significant differ-
ences in lipid and apolipoprotein concentrations between pa-
tients with 24 hour urinary protein excretion exceeding 3.5 g
and patients with lower 24 hour urinary protein excretion.
Cardioselective beta blockers were used by a high proportion
of diabetic and nondiabetic patients with renal insufficiency.
These agents may contribute to certain lipid abnormalities as
described earlier [13]. However, the proportion of patients
treated with 13-blockers was the same in both groups of patients
with nephropathy. Thus, comparison of diabetic and non-
diabetic patients with renal insufficiency should not be biased
by this factor.
Only a few studies have focused on lipid and apolipoprotein
measurements in diabetic patients with renal failure. In a recent
study, Avram et al observed that diabetic patients on CAPD
had lower levels of ApoB than non-diabetic patients, despite
similar lipid and ApoA-I levels [25]. Sniderman et al also
reported that diabetic patients on CAPD had lower levels of
LDL-ApoB than non-diabetics [26]. In the present study, there
was, however, no difference in ApoB levels between diabetic
and non-diabetic patients with renal insufficiency. In hemodial-
ysis patients, Avram et al found that, despite similar plasma TG
levels, insulin-dependent diabetics had higher concentrations of
HDL-cholesterol than non-diabetic patients resulting in a more
favorable ratio of HDL-cholesterol/non-HDL-cholesterol [6].
Results of the present study have shown that among the
diabetic patients, only those with GFR > 20 mI/mm have a
higher HDL-choiesteroi/non-HDL-cholesterol ratio than non-
diabetic patients; there was no difference in this ratio in patients
with GFR  20 ml/min. Jensen et al have reported that diabetic
patients with nephropathy, as determined by significant protein-
uria, have increased concentrations of plasma TC and TG as
well as increased concentrations of VLDL-cholesterol and
LDL-cholesterol in comparison with diabetic patients without
proteinuria [27]. Although the increase in serum creatinine
levels in the proteinuric patients was very modest, with a mean
value of 95 tmol/liter, it is possible that the values of GFR were
reduced in some of these patients. This observation is in line
with similar findings in this and other studies of non-diabetic
patients, demonstrating that significant abnormalities of plasma
apolipoprotein profiles may be disclosed even at moderately
reduced GFR levels [13, 21]. Increased concentrations of TG,
LDL-cholesterol and ApoB have also been detected in diabetic
patients with microalbuminuria but normal GFR [28].
The complex pathogenesis of the dyslipoproteinemia of dia-
betic renal insufficiency requires further characterization and
may be influenced not only by the decrease in renal function but
also by the metabolic control, the degree of proteinuria and,
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although not evaluated in the present study, by nutritional
status and pharmacological treatment. Most studies suggest
that the accumulation in non-diabetic renal insufficiency of
intact or partially metabolized TG-rich ApoB-containing 11-
poproteins is due to their defective catabolism and/or removal
rather than overproduction [29—35]. The main reasons for
defective catabolism of TG-rich lipoproteins are reduced activ-
ities of plasma and tissue lipoprotein lipase and hepatic lipase,
compositional alterations of lipoprotein substrates for lipolysis
and receptor and non-receptor mediated uptake [35—41]. For
example, increased TG content and changes in the proportions
of individual TG-rich lipoprotein particles favoring increased
ApoC-III/ApoE ratios may render these lipoproteins less suit-
able for degradation and/or uptake [32, 35, 42]. It has been
suggested that in non-diabetic renal insufficiency, insulin defi-
ciency or resistance may contribute significantly to the reduced
activity of lipoprotein lipase [41, 43, 44] and directly affect the
properties of lipoprotein substrates [45]. It remains to be
determined to what extent impaired insulin action may be
operative in diabetic renal failure. In insulin-dependent diabe-
tes, insulin deficiency may lead to the accumulation of TG-rich
lipoproteins through their increased production from fatty acids
mobilized from adipose tissue and decreased removal due to
reduced lipoprotein lipase activity [46, 47].
The lipoprotein abnormalities in diabetic patients with renal
insufficiency have some characteristics that could be consid-
ered atherogenic including reduced levels of HDL-cholesterol
and apolipoproteins A-I and A-Il and increased levels of TC and
ApoB. The unresolved question of the atherogenic potential of
TG-rich ApoB-containing lipoprotein particles accumulating in
diabetic patients with renal failure represents an equally impor-
tant problem. Although the relative atherogenicity of these
lipoproteins remains to be determined, several recent studies
have suggested that elevated concentrations of some intact
andlor partially delipidized TG-rich lipoproteins (lipoprotein
"remnants") may represent an increased risk for premature
vascular disease [48—50]. It is, therefore, possible, although not
proven, that dyslipoproteinemia of diabetic renal failure may
contribute to the development of atherosclerosis reflected in
high rates of vascular complications in these patients before and
during dialysis and after renal transplantation. Whether it also
contributes to the progression of diabetic nephropathy as re-
cently suggested by Mulec et al [511 remains to be established in
future studies.
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